Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04994977 · ClinicalTrials.gov registry record · Phase 1
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
A Phase 1 study of Choroid Plexus Carcinoma and Atypical Choroid Plexus Papilloma, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT04994977 is a Phase 1 study of Choroid Plexus Carcinoma and Atypical Choroid Plexus Papilloma that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 1 participants, below the 533-participant average among 3 other Choroid Plexus Carcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04994977, a Phase 1 study of Choroid Plexus Carcinoma and Atypical Choroid Plexus Papilloma, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the safety and efficacy of intra-arterial chemotherapy in subjects with newly diagnosed, residual, or recurrent atypical choroid plexus papilloma and choroid plexus carcinoma prior to a second surgery. It is believed that intra-arterial chemotherapy will be safe and feasible for this population and will result in decreased tumor size, which may further improve the goals of a second-look surgery.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Carboplatin
- DRUG Topotecan
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04994977
The ClinicalTrials.gov registry entry for NCT04994977 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 533-participant average among 3 other Choroid Plexus Carcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Choroid Plexus Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Melphalan is the first listed.
NCT04994977 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04994977 about?
NCT04994977 is a clinical study titled "Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery". This study will test the safety and efficacy of intra-arterial chemotherapy in subjects with newly diagnosed, residual, or recurrent atypical choroid plexus papilloma and choroid plexus carcinoma prior to a second surgery. It is believed that intra-arterial chemotherapy will be safe and feasible fo...
What is the current status of trial NCT04994977?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2023-05-04. Estimated completion is 2026-12.
What conditions does trial NCT04994977 study?
This clinical trial studies the following conditions: Choroid Plexus Carcinoma, Atypical Choroid Plexus Papilloma.
What interventions are being tested in trial NCT04994977?
The interventions under investigation include: Melphalan (DRUG), Carboplatin (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT04994977?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04994977 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroid Plexus Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.